We are live on ! Find out more
ABCL icon

AbCellera Biologics
ABCL

141 hedge funds and large institutions have $525M invested in AbCellera Biologics in 2025 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 43 increasing their positions, 35 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more call options, than puts

Call options by funds: $9.54M | Put options by funds: $5.18M

59% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 22

42% more capital invested

Capital invested by funds: $371M → $525M (+$154M)

23% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 35

10% more funds holding

Funds holding: 128 → 141 (+13)

1.25% less ownership

Funds ownership: 36.07% → 34.81% (-1.3%)

Holders
141
Holders Change
+13
Holders Change %
+10.16%
% of All Funds
1.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
35
Increased
43
Reduced
35
Closed
22
Calls
$9.54M
Puts
$5.18M
Net Calls
+$4.35M
Net Calls Change
+$2.71M

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$9.67M
2
Morgan Stanley
Morgan Stanley
New York
+$7.91M
3
DCM
Driehaus Capital Management
Illinois
+$5.41M
4
Two Sigma Investments
Two Sigma Investments
New York
+$4.69M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.63M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$29.1M
2
O
OrbiMed
New York
-$11.5M
3
Citadel Advisors
Citadel Advisors
Florida
-$8.29M
4
Millennium Management
Millennium Management
New York
-$4.27M
5
UBS Group
UBS Group
Switzerland
-$4.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Rockefeller Capital Management
126
Rockefeller Capital Management
New York
$12.6K +$11K +2,500 New
BCM
127
Blume Capital Management
California
$10.6K +$9.25K +2,100 New
US Bancorp
128
US Bancorp
Minnesota
$7.42K +$383 +87 +6%
QCG
129
Quadrant Capital Group
Ohio
$7.19K +$6.3K +1,429 New
PS
130
Principal Securities
Iowa
$6.32K – – –
Daiwa Securities Group
131
Daiwa Securities Group
Japan
$6K – – –
AF
132
Allworth Financial
California
$5.93K +$912 +207 +21%
PGAM
133
Princeton Global Asset Management
New Jersey
$5.03K +$4.41K +1,000 New
WANY
134
Wealthspire Advisors (New York)
New York
$3.97K +$3.48K +790 New
Jones Financial Companies
135
Jones Financial Companies
Missouri
$3.32K – – –
Nisa Investment Advisors
136
Nisa Investment Advisors
Missouri
$3.07K – – –
BRWA
137
B. Riley Wealth Advisors
Florida
$2.52K +$2.2K +500 New
NA
138
NewEdge Advisors
Louisiana
$1.51K – – –
MCM
139
MAI Capital Management
Ohio
$1.34K -$3.31K -752 -74%
PWA
140
Physician Wealth Advisors
Utah
$846 +$740 +168 New
CPG
141
Cornerstone Planning Group
New Jersey
$741 +$150 +34 New
UBS AM
142
UBS AM
Illinois
– -$29.1M -8,471,619 Closed
O
143
OrbiMed
New York
– -$11.5M -3,344,568 Closed
NHAS
144
Novo Holdings A/S
Denmark
– -$2.24M -652,529 Closed
Norges Bank
145
Norges Bank
Norway
– -$2.16M -630,938 Closed
VF
146
Virtu Financial
New York
– -$709K -206,710 Closed
PAMP
147
Polar Asset Management Partners
Ontario, Canada
– -$548K -159,800 Closed
PEAK6
148
PEAK6
Illinois
– -$602K -136,614 Closed
TI
149
TrueMark Investments
Illinois
– -$381K -111,119 Closed
EC
150
EntryPoint Capital
New York
– -$307K -89,570 Closed
3 4 5
6
7

ABCL Hedge Fund Activity: Q3 2025 in Review

141 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q3 2025, worth a combined $525M — up 42% from $371M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ABCL positions and 22 closed out — a net gain of 13 holders — while 43 added to existing stakes and 35 trimmed.

The largest buyer was Bank of America, adding an estimated $9.67M. The largest seller was UBS AM, exiting entirely with an estimated $29.1M sold.

  • 141 institutional investors held AbCellera Biologics (ABCL) as of Q3 2025, up from 128 in Q2 2025.
  • Funds reported $525M of AbCellera Biologics stock for Q3 2025, up 42% quarter-over-quarter.
  • 35 funds opened new AbCellera Biologics positions in Q3 2025 and 22 closed out, a net change of +13 holders.
  • The largest AbCellera Biologics buyer in Q3 2025 was Bank of America, an estimated $9.67M added.
  • The largest AbCellera Biologics seller in Q3 2025 was UBS AM, an estimated $29.1M sold.

Based on aggregated 13F filings for Q3 2025.